[HTML][HTML] Pirfenidone attenuates lung fibrotic fibroblast responses to transforming growth factor-β1
J Jin, S Togo, K Kadoya, M Tulafu, Y Namba, M Iwai… - Respiratory …, 2019 - Springer
Background Pirfenidone, an antifibrotic agent used for the treatment of idiopathic pulmonary
fibrosis (IPF), functions by inhibiting myofibroblast differentiation, which is involved in …
fibrosis (IPF), functions by inhibiting myofibroblast differentiation, which is involved in …
[HTML][HTML] Pirfenidone inhibits TGF-β1-induced over-expression of collagen type I and heat shock protein 47 in A549 cells
K Hisatomi, H Mukae, N Sakamoto, Y Ishimatsu… - BMC Pulmonary …, 2012 - Springer
Background Pirfenidone is a novel anti-fibrotic and anti-inflammatory agent that inhibits the
progression of fibrosis in animal models and in patients with idiopathic pulmonary fibrosis …
progression of fibrosis in animal models and in patients with idiopathic pulmonary fibrosis …
[HTML][HTML] Anti-fibrotic effects of pirfenidone and rapamycin in primary IPF fibroblasts and human alveolar epithelial cells
M Molina-Molina, C Machahua-Huamani… - BMC pulmonary …, 2018 - Springer
Background Pirfenidone, a pleiotropic anti-fibrotic treatment, has been shown to slow down
disease progression of idiopathic pulmonary fibrosis (IPF), a fatal and devastating lung …
disease progression of idiopathic pulmonary fibrosis (IPF), a fatal and devastating lung …
Effect of pirfenidone on proliferation, TGF-β-induced myofibroblast differentiation and fibrogenic activity of primary human lung fibroblasts
E Conte, E Gili, E Fagone, M Fruciano… - European Journal of …, 2014 - Elsevier
Pirfenidone is an orally active small molecule that has been shown to inhibit the progression
of fibrosis in animal models and in patients with idiopathic pulmonary fibrosis. Although …
of fibrosis in animal models and in patients with idiopathic pulmonary fibrosis. Although …
Pirfenidone: molecular mechanisms and potential clinical applications in lung disease
SM Ruwanpura, BJ Thomas… - American journal of …, 2020 - atsjournals.org
Pirfenidone (PFD) is a pharmacological compound with therapeutic efficacy in idiopathic
pulmonary fibrosis. It has been chiefly characterized as an antifibrotic agent, although it was …
pulmonary fibrosis. It has been chiefly characterized as an antifibrotic agent, although it was …
[HTML][HTML] Interferon-γ enhances the antifibrotic effects of pirfenidone by attenuating IPF lung fibroblast activation and differentiation
TN Vu, X Chen, HD Foda, GC Smaldone… - Respiratory …, 2019 - Springer
Background Idiopathic pulmonary fibrosis (IPF) pathogenesis involves multiple pathways,
and combined antifibrotic therapy is needed for future IPF therapy. Inhaled interferon-γ (IFN …
and combined antifibrotic therapy is needed for future IPF therapy. Inhaled interferon-γ (IFN …
[HTML][HTML] Evaluation of pirfenidone and nintedanib in a human lung model of fibrogenesis
KM Roach, E Castells, K Dixon, S Mason… - Frontiers in …, 2021 - frontiersin.org
Introduction: Idiopathic pulmonary fibrosis (IPF) is a progressive, fatal lung disease with a
poor prognosis and increasing incidence. Pirfenidone and nintedanib are the only approved …
poor prognosis and increasing incidence. Pirfenidone and nintedanib are the only approved …
Antifibrotic activities of pirfenidone in animal models
CJ Schaefer, DW Ruhrmund, L Pan… - European …, 2011 - Eur Respiratory Soc
Pirfenidone is an orally active small molecule that has recently been evaluated in large
clinical trials for the treatment of idiopathic pulmonary fibrosis, a fatal disease in which the …
clinical trials for the treatment of idiopathic pulmonary fibrosis, a fatal disease in which the …
[HTML][HTML] Pirfenidone anti-fibrotic effects are partially mediated by the inhibition of MUC1 bioactivation
B Ballester, J Milara, J Cortijo - Oncotarget, 2020 - ncbi.nlm.nih.gov
Pirfenidone is a pleiotropic molecule approved to treat idiopathic pulmonary fibrosis (IPF).
Pirfenidone has demonstrated to downregulate transforming growth factor-β1 (TGF-β1) …
Pirfenidone has demonstrated to downregulate transforming growth factor-β1 (TGF-β1) …
Efficacy and safety of pirfenidone for idiopathic pulmonary fibrosis
Y Takeda, K Tsujino, T Kijima… - Patient preference and …, 2014 - Taylor & Francis
Idiopathic pulmonary fibrosis (IPF) is a devastating chronic fibrotic lung disease. Although
the precise cause of the disease is still unknown, recent studies have shown that the …
the precise cause of the disease is still unknown, recent studies have shown that the …